FDA Warns Two Contract Research Sites Over Protocol Violations
Comprehensive Clinical Research has made several personnel changes in response to an FDA inspection that resulted in a June 5 warning letter
You may also be interested in...
Forest will launch its non-CFC version of the prescription asthma inhaler Aerobid (flunisolide) this fall, President and Chief Operating Officer Kenneth Goodman told analysts on a conference call Jan. 16.
Roche/Gilead Tamiflu updated labeling includes data from a seasonal prophylaxis study in elderly nursing home residents who took oseltamivir for 42 days.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011